Literature DB >> 25556446

Association of CYP39A1, RUNX2 and oxidized alpha-1 antitrypsin expression in relation to cholangiocarcinoma progression.

Chakkaphan Khenjanta1, Raynoo Thanan, Apinya Jusakul, Anchalee Techasen, Wassana Jamnongkan, Nisana Namwat, Watcharin Loilome, Chawalit Pairojkul, Puangrat Yongvanit.   

Abstract

Cytochrome P450 (CYP) enzymes are a large family of constitutive and inducible mono-oxygenase enzymes that play a central role in the oxidative metabolism of both xenobiotic and endogenous compounds. Several CYPs are involved in metabolism of oxysterols, which are cholesterol oxidation products whose expression may be dysregulated in inflammation-related diseases including cancer. This study focused on CYP39A1, which can metabolize 24-hydroxycholesterol (24-OH) that plays important roles in the inflammatory response and oxidative stress. We aimed to investigate the expression status of CYP39A1 and its transcription factor (RUNX2) in relation to clinical significance in cholangiocarcinoma (CCAs) and to determine whether 24-OH could induce oxidative stress in CCA cell lines. Immunohistochemistry showed that 70% and 30% of CCA patients had low and high expression of CYP39A1, respectively. Low expression of CYP39A1 demonstrated a significant correlation with metastasis. Our results also revealed that the expression of RUNX2 had a positive correlation with CYP39A1. Low expression of both CYP39A1 (70%) and RUNX2 (37%) was significantly related with poor prognosis of CCA patients. Interestingly, oxidized alpha-1 antitrypsin (ox-A1AT), an oxidative stress marker, was significantly increased in CCA tissues in which CYP39A1 and RUNX2 were down regulated. Additionally, immunocytochemistry showed that 24-OH could induce ox-A1AT in CCA cell lines. In conclusion, our study revealed putative roles of the CYP39A1 enzyme in prognostic determination of CCAs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25556446     DOI: 10.7314/apjcp.2014.15.23.10187

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

Review 1.  Liver fluke infection and cholangiocarcinoma: a review.

Authors:  Shuohan Zheng; Yuan Zhu; Zijun Zhao; Zhongdao Wu; Kamolnetr Okanurak; Zhiyue Lv
Journal:  Parasitol Res       Date:  2016-10-08       Impact factor: 2.289

2.  Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.

Authors:  Venil N Sumantran; Pratik Mishra; Rakesh Bera; Natarajan Sudhakar
Journal:  Pharmaceutics       Date:  2016-02-17       Impact factor: 6.321

3.  A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.

Authors:  Stéphanie Durand; Killian Trillet; Arnaud Uguen; Aude Saint-Pierre; Catherine Le Jossic-Corcos; Laurent Corcos
Journal:  BMC Genomics       Date:  2017-09-30       Impact factor: 3.969

4.  Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome.

Authors:  Dan Li; Tao Yu; Junjie Hu; Jie Wu; Shi Feng; Qingxue Xu; Hua Zhu; Xu Zhang; Yonggang Zhang; BenHong Zhou; Lijuan Gu; Zhi Zeng
Journal:  Oxid Med Cell Longev       Date:  2021-12-31       Impact factor: 6.543

5.  Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer.

Authors:  Rebecca Swan; Abdo Alnabulsi; Beatriz Cash; Ayham Alnabulsi; Graeme I Murray
Journal:  Oncotarget       Date:  2016-07-19

6.  Comprehensive analysis of DNA methylation and gene expression profiles in cholangiocarcinoma.

Authors:  Cheng Zhang; Bingye Zhang; Di Meng; Chunlin Ge
Journal:  Cancer Cell Int       Date:  2019-12-26       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.